These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 39084211)
41. Novel data-driven subtypes and stages of brain atrophy in the ALS-FTD spectrum. Shen T; Vogel JW; Duda J; Phillips JS; Cook PA; Gee J; Elman L; Quinn C; Amado DA; Baer M; Massimo L; Grossman M; Irwin DJ; McMillan CT Transl Neurodegener; 2023 Dec; 12(1):57. PubMed ID: 38062485 [TBL] [Abstract][Full Text] [Related]
42. Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. Pathak N; Vimal SK; Tandon I; Agrawal L; Hongyi C; Bhattacharyya S Metab Brain Dis; 2022 Jan; 37(1):67-104. PubMed ID: 34719771 [TBL] [Abstract][Full Text] [Related]
43. Identifying an Optimal Neuroinflammation Treatment Using a Nanoligomer Discovery Engine. Sharma S; Borski C; Hanson J; Garcia MA; Link CD; Hoeffer C; Chatterjee A; Nagpal P ACS Chem Neurosci; 2022 Dec; 13(23):3247-3256. PubMed ID: 36410860 [TBL] [Abstract][Full Text] [Related]
44. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides. Singh K; Gupta JK; Kumar S; Soni U Curr Protein Pept Sci; 2024; 25(7):507-526. PubMed ID: 38561605 [TBL] [Abstract][Full Text] [Related]
45. Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Weishaupt JH; Hyman T; Dikic I Trends Mol Med; 2016 Sep; 22(9):769-783. PubMed ID: 27498188 [TBL] [Abstract][Full Text] [Related]
46. TDP-43 and Inflammation: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Bright F; Chan G; van Hummel A; Ittner LM; Ke YD Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360544 [TBL] [Abstract][Full Text] [Related]
47. Granulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology. de Majo M; Koontz M; Marsan E; Salinas N; Ramsey A; Kuo YM; Seo K; Li H; Dräger N; Leng K; Gonzales SL; Kurnellas M; Miyaoka Y; Klim JR; Kampmann M; Ward ME; Huang EJ; Ullian EM Stem Cell Reports; 2023 Mar; 18(3):706-719. PubMed ID: 36827976 [TBL] [Abstract][Full Text] [Related]
56. Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases. Hart de Ruyter FJ; Evers MJAP; Morrema THJ; Dijkstra AA; den Haan J; Twisk JWR; de Boer JF; Scheltens P; Bouwman FH; Verbraak FD; Rozemuller AJ; Hoozemans JJM Acta Neuropathol; 2024 Aug; 148(1):24. PubMed ID: 39160362 [TBL] [Abstract][Full Text] [Related]
57. Modeling Neurodegenerative Microenvironment Using Cortical Organoids Derived from Human Stem Cells. Yan Y; Song L; Bejoy J; Zhao J; Kanekiyo T; Bu G; Zhou Y; Li Y Tissue Eng Part A; 2018 Jul; 24(13-14):1125-1137. PubMed ID: 29361890 [TBL] [Abstract][Full Text] [Related]
58. Cyclin F, Neurodegeneration, and the Pathogenesis of ALS/FTD. Rayner SL; Hogan A; Davidson JM; Cheng F; Luu L; Morsch M; Blair I; Chung R; Lee A Neuroscientist; 2024 Apr; 30(2):214-228. PubMed ID: 36062310 [TBL] [Abstract][Full Text] [Related]
59. Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations. Le NT; Chang L; Kovlyagina I; Georgiou P; Safren N; Braunstein KE; Kvarta MD; Van Dyke AM; LeGates TA; Philips T; Morrison BM; Thompson SM; Puche AC; Gould TD; Rothstein JD; Wong PC; Monteiro MJ Proc Natl Acad Sci U S A; 2016 Nov; 113(47):E7580-E7589. PubMed ID: 27834214 [TBL] [Abstract][Full Text] [Related]